PharmaTech

JUNE 26, 2025

million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). million (approximately US$1.99 million (approximately US$1.99 million (approximately US$1.99 The company said in June 2025 that it raised €11.25 million (US$12.9

Dosage 59

Dosage Drug Development Vaccines Labelling 59

Express Pharma

NOVEMBER 26, 2024

With the Indian pharma market projected to grow to $ 130 billion by 2030 and $ 450 billion by 2047, the event highlighted the industry’s vital role in shaping global healthcare. Projections indicate exports will soar to $130 billion by 2030 and $450 billion by 2047. trillion.

Packaging 105

Packaging Biosimilars Pharmaceutical Manufacturing Dosage 105

PharmaTech

JULY 7, 2025

billion) by 2030 (1). One-quarter of patients who suffer a hip fracture die within one year, Theramex said, with hip fractures costing NHS £2 billion (US$2.7 billion) per year and osteoporotic fractures presently accounting for more than £4.6 billion (US$6.3 billion) of direct costs to NHS, forecast to increase to £6 billion (US$8.2

Dosage 49

Dosage Drug Development Chemotherapy Vaccines 49

European Pharmaceutical Review

OCTOBER 7, 2022

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Leading companies in the oral solid dosage market are Catalent, Inc.,

Dosage 98

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 98

Express Pharma

JANUARY 2, 2025

million by 2030. The post Akums announces new facility for lyophilized and sterile dosage manufacturing appeared first on Express Pharma. The global lyophilized injectables market, estimated at a value of approximately $ 3,365.4 million in 2023, is expected to experience steady growth, reaching an impressive $4,978.3 With a CAGR of 5.6

Dosage 52

Dosage Compounding 52

European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. According to the report buccal delivery is the “most feasible and preferred choice compared to oral dosage forms, particularly among elderly patients.” The sublingual films segment is projected to grow at the highest rate during the forecast period 2023-2030.

Dosage 52

Dosage Compounding 52

European Pharmaceutical Review

FEBRUARY 3, 2023

The HPAPI market A 2022 market report showed that due to the small volumes required for dosage, small-scale providers are also gaining importance. billion by 2030 The post France gets new sterile liquid drug manufacturing facility appeared first on European Pharmaceutical Review. HPAPI contract manufacturing to value $14.6

Dosage 98

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 98

Express Pharma

APRIL 10, 2025

This expansion represents a pivotal moment in Morepens journey as we sharpen our focus on the expanding domestic finished dosage market, said Sushil Suri, Chairman and Managing Director of Morepen Laboratories. The Indian pharmaceutical market is projected to reach $130 billion by 2030, with an estimated annual growth rate of 8.2

Dosage 66

Dosage 66

European Pharmaceutical Review

JANUARY 4, 2023

A report has estimated that the oral solid dosage (OSD) contract manufacturing market will be valued at $54.7 billion by 2030. Oral solids. Oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes.

Dosage 52

Dosage Drug Development 52

Express Pharma

MAY 22, 2023

This, in turn, has opened a huge opportunity for the nutraceuticals industry globally and India is uniquely positioned to become one of the most formidable players in this segment, with a projected $100 billion valued market by 2030. Read: [link] www.expresspharma.in/six-reasons-why-india-is-poised-to-be-aglobal-leader-in-nutraceuticals/

Dosage 105

Dosage Method Validation Labelling Immunization 105

European Pharmaceutical Review

OCTOBER 18, 2022

billion by 2030, according to a market report. However, due to the small volumes required for dosage, small-scale providers are also gaining importance, findings from the report show. The Asia Pacific region is expected to register the fastest growth from 2022-2030 due to the presence of the large HPAPI manufacturers in China.

Dosage 105

Dosage Vaccines 105

European Pharmaceutical Review

SEPTEMBER 7, 2022

The second most commonly used pharmaceutical dosage form, capsules, are anticipated to be a $5.2 billion market by 2030, growing from a 2020 value of around $2.4 Compared with other oral solid dosage forms (OSDs), capsules also offer the easiest method to achieve fixed-dose combinations (FDCs) of incompatible drug substances.

Dosage 124

Dosage Vaccines Diabetes 124

PharmaTech

JULY 1, 2025

Recent Videos Related Content Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report Susan Haigney June 30th 2025 Article The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

Dosage 45

Dosage Packaging Drug Development Vaccines 45

PharmaTech

JUNE 10, 2025

The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1).

Dosage 52

Dosage Drug Development Vaccines Compounding 52

PharmaTech

JUNE 11, 2025

The financing round was co-led by Kurma Partners , WE Life Sciences , and the French Tech Seed Fund managed by Bpifrance , on behalf of the French government, under the France 2030 initiative. Additional participants included Argobio , Angelini Ventures , CARMA Fund , Capital Grand Est , and Sambrinvest.

Dosage 52

Dosage Drug Development Packaging Vaccines 52